| | |  | | | | Record from Web of Science® | | | | | | |
| Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? |
|
|
| Author(s): Blanchard F, Chipoy C |
| Source: DRUG DISCOVERY TODAY Volume: 10 Issue: 3 Pages: 197-204 Published: FEB 1 2005 |
| Times Cited: 65 References: 61 |
| Abstract: Histone deacetylase (HDAC) inhibitors induce cell cycle arrest and differentiation in cancer cells and have been in Phase I-II clinical trials for the treatment of various solid or haematological malignancies. In recent years, HDAC inhibitors have emerged as potent contenders for anti-inflammatory drugs, offering new lines of therapeutic intervention for rheumatoid arthritis or lupus erythematosus. The molecular mode of action of HDAC inhibitors is still controversial but seems to rely on reduced inflammatory mediator production, such as nitric oxide or cytokines, which implies inhibition of the transcription factor NF-kappaB. These anti-inflammatory effects will hopefully lead us to appreciate the complex anti-tumour effects of HDAC inhibitors. |
| Document Type: Review |
| Language: English |
| Reprint Address: Blanchard, F (reprint author), Univ Nantes, EA 3822, Lab Pathophysiol Bone Resorpt & Therapy Primit Bo, 1 Rue Gaston Veil, F-44035 Nantes 1, France |
Addresses:
1. Univ Nantes, EA 3822, Lab Pathophysiol Bone Resorpt & Therapy Primit Bo, F-44035 Nantes 1, France
2. INSERM, ER17, F-44035 Nantes, France |
| Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND |
| Subject Category: Pharmacology & Pharmacy |
| IDS Number: 893CD |
| ISSN: 1359-6446 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |